Date: 2016-09-26
Type of information: Licensing agreement
Compound: ONC-392
Company: Pfizer (USA - NY) OncoImmune (USA - MD)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: monoclonal antibody/immune checkpoint inhibitor. ONC-392 is a preclinical anti-CTLA4 monoclonal antibody.
Disease:
Details: * On September 15, 2016, OncoImmune announced that it has entered into an exclusive option and license agreement with Pfizer for ONC-392, a novel, differentiated preclinical anti-CTLA4 monoclonal antibody in a deal worth up to $250 million in upfront and potential milestone payments. Under the terms of the agreement, Pfizer plans to evaluate ONC-392 up until a certain agreed-upon time to determine whether it will exercise its option to exclusively license ONC-392 as well as any other OncoImmune anti-CTLA4 antibodies. If Pfizer exercises its option under the agreement, Pfizer would be responsible for all development and potential commercialization of the program, and OncoImmune would be eligible to receive potential developmental and commercial milestone payments as well as royalties, tiered from mid-single up to low-double digits, on sales of any potential resulting products.
Financial terms:
Latest news:
